Results 151 to 160 of about 41,565 (267)

Psychedelics, entactogens and psychoplastogens for depression and related disorders

British Journal of Pharmacology, Volume 183, Issue 14, Page 3897-3919, July 2026.
Currently, the most actively investigated rapidly acting antidepressants, anxiolytics and/or anti PTSD agents, include psychedelics e.g. psilocybin, LSD, N,N‐dimethyltryptamine, ayahuasca; non‐hallucinogenic entactogens, e.g. MDMA; psychoplastogens which rapidly promote neuroplasticity, e.g.
Daniel Hoyer
wiley   +1 more source

Multiple sclerosis: Intrathecal inflammation mediates mood in relapsing–remitting multiple sclerosis

, 2017
In Brief comment on original article Rossi, S. et al. Neuroinflammation drives anxiety and depression in relapsing–remitting multiple sclerosis. Neurology http://dx.doi.org/10.1212/ WNL.0000000000004411 (2017)A new study has revealed that subclinical ...
Patel, Mitesh
core  

PBPK Modeling and Clinical Data Reveal Reduced Impact of CYP3A4 and CYP2C9 Inhibitors on Elimination of Siponimod

Clinical and Translational Science, Volume 19, Issue 7, July 2026.
ABSTRACT Multiple sclerosis (MS) is a significant cause of neurological disability in young adults. Siponimod, a potent sphingosine‐1‐phosphate (S1P) receptor modulator, is used to treat MS by reducing T‐cell recirculation and central inflammation. The presented work includes clinical data describing the impact of the CYP3A4 inhibitor clarithromycin on
Felix Huth, Kasra Shakeri‐Nejad, Anne Gardin, Bharti Shah, Oliver Pohl, Nicole Pezous, Thomas Faller   +6 more
wiley   +1 more source

Reducing the Probability of False Positive Research Findings by Pre-Publication Validation - Experience with a Large Multiple Sclerosis Database

, 2007
*Objective* We have assessed the utility of a pre-publication validation policy in reducing the probability of publishing false positive research findings.
Moritz M. Heinz, Martin M. Daumer, Katja K. Ickstadt, Siegfried S. Schach, Ulrike U. Held, George G. Ebers   +5 more
core  

Manufacturing and clinical applications of non‐CAR‐T immune effector cells

Transfusion, EarlyView.
Thane Kubik, Theodros Mamo, David H. McKenna   +2 more
wiley   +1 more source

Gingival and Periodontal Diseases and Conditions in Children and Adolescents: Consensus Report

Journal of Clinical Periodontology, Volume 53, Issue 7, Page 1068-1099, July 2026.
ABSTRACT Background The objectives of this Focused Workshop were to update the epidemiology, aetiology, risk factors, diagnosis and management of gingival and periodontal diseases and conditions in children and adolescents, and to explore the applicability of the 2018 Classification in children and adolescents.
Iain Chapple, Sotiria Gizani, Mariano Sanz, Dominique Declerck, Phoebus Madianos, Valerie Clerehugh, Monique Danser, Esti Davidovich, Janet Davies, Nikos Donos, Elisabeth Dursun, Elena Figuero, Filippo Graziani, Mervi Gursoy, Soren Jepsen, Clara Joseph, Moritz Kebschull, Norbert Kraemer, Tina Lambrinaki, Rodrigo López, David J. Manton, Joerg Meyle, Ana Molina, Lior Shapira, Cheryl Somani, Georgios Tsilingaridis, Svante Twetman, Nicola West, Biniyam Wondimu, Ferranti Wong, David Herrera   +30 more
wiley   +1 more source

Asian Pacific Association of Gastroenterology (APAGE) Clinical Practice Guidelines on the Use of Small Molecules and IL‐23 p19 Inhibitors in Ulcerative Colitis and Crohn's Disease

Journal of Gastroenterology and Hepatology, Volume 41, Issue 7, Page 2006-2029, July 2026.
ABSTRACT Ulcerative colitis (UC) and Crohn's disease (CD) are increasingly prevalent in the Asia Pacific region, necessitating updated, region‐specific guidance on advanced therapies. Targeted small molecule agents, such as filgotinib, tofacitinib, upadacitinib, etrasimod, and ozanimod; and the IL‐23 p19 inhibitors (guselkumab, mirikizumab ...
Choon Jin Ooi, Khoon Lin Ling, Julajak Limsrivilai, Shu‐Chen Wei, Joyce Wing Yan Mak, Taku Kobayashi, Luan Minh Dang, Rupert W. Leong, Huiyu Lin, Meng‐Tzu Weng, Wan Chee Ong, Vineet Ahuja, Satimai Aniwan, Ryota Hokari, Wei Jie Jonathan Lee, Alex Hwong‐Ruey Leow, Wai‐Keung Leung, Wee‐Chian Lim, Govind Makharia, Katsuyoshi Matsuoka, Nazri Mustaffa, Siew‐Chien Ng, Mathew Philip, Pises Pisespongsa, Raja Affendi Raja Ali, Zhi Hua Ran, Marcellus Simadibrata, Jose Sollano, Malcolm Tan, Hang Dao Viet, Nik Razima Wan Ibrahim, Kai Chun Wu, Byong Duk Ye, Ida Hilmi, Asian Pacific Association of Gastroenterology (APAGE) Inflammatory Bowel Disease Committee and Asian Education Network in IBD (AEN‐IBD)   +34 more
wiley   +1 more source

Comparing the Efficacy of Monthly Cyclophosphamide as Monotherapy versus Daily Fingolimod in Relapsing Remitting and Secondary Progressive Multiple Sclerosis

مجله دانشکده پزشکی اصفهان, 2017
Background: The aim of this study was to determine the efficacy of monthly cyclophosphamide and daily fingolimod in treatment of patients with multiple sclerosis (MS) and to compare these two treatment strategies.
Vahid Shaygannezhad, Hassan Amini
doaj  

Interferons in relapsing remitting multiple sclerosis

The Lancet, 2003
openaire   +2 more sources

Multiomics Profiling During Autoimmune Demyelination Highlights a Complex Regulatory Role for Ataxin‐1 in B Cells

Annals of the New York Academy of Sciences, Volume 1561, Issue 1, July 2026.
Ataxin‐1 has been recently implicated in B cell regulation in the context of multiple sclerosis pathology. In this study, we used a multiomics pipeline to profile the B cell transcriptome, epigenome, and proteome in response to encephalitogenic challenges.
Jonathan J. Carver, Rachael R. Denbrock, Kristy M. Lau, Tonya N. Zeczycki, Changhong Yin, Weihua Huang, Alessandro Didonna   +6 more
wiley   +1 more source